Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011)
Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.
Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PM
Session Title: Leukemia, Myelodysplasia and Transplantation
Location: Arie Crown Theater
Oral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)
Abstract # 122
Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study. S. O'Brien et al.
Date/Time: Friday, June 17, 2011; 9:45 AM
Session 10: Chronic Lymphocytic Leukemia (CLL)
Location: Room A, B, C and Marquee Parco Ciani)
Abstract # 153
Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study. R.H. Advani et al.
Date/Time: Saturday, June 18, 2011; 9:30 AM
Session 14: Signaling Pathways in Lymphoma
Location: Room A
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All